Search Results - "OHORI, H" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

by Yamada, Y., Denda, T., Gamoh, M., Iwanaga, I., Yuki, S., Shimodaira, H., Nakamura, M., Yamaguchi, T., Ohori, H., Kobayashi, K., Tsuda, M., Kobayashi, Y., Miyamoto, Y., Kotake, M., Shimada, K., Sato, A., Morita, S., Takahashi, S., Komatsu, Y., Ishioka, C.
Published in Annals of oncology (01.03.2018)

Get full text

Journal Article

RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC)

RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC)

by Sunakawa, Y., Nakamura, M., Ishizaki, M., Kataoka, M., Satake, H., Kitazono, M., Yanagisawa, H., Kawamoto, Y., Kuramochi, H., Ohori, H., Nakamura, M., Takahashi, K., Maeda, F., Komeno, C., Takeuchi, M., Fujii, M., Yoshino, T., Ichikawa, W., Tsuji, A.
Published in Annals of oncology (01.07.2019)

Get full text

Journal Article

A feasibility study of edoxaban for the cancer-associated asymptomatic venous thromboembolism in Japanese gastrointestinal cancer patients receiving chemotherapy (ExCAVE study)

A feasibility study of edoxaban for the cancer-associated asymptomatic venous thromboembolism in Japanese gastrointestinal cancer patients receiving chemotherapy (ExCAVE study)

by Nakamura, M., Yagisawa, M., Saiki, T., Ishiguro, A., Sawada, K., Yuki, S., Sasaki, T., Ando, T., Ohori, H., Kotaka, M., Muto, O., Shindo, Y., Nakashima, K., Hosokawa, A., Doi, A., Izawa, N., Sunakawa, Y., Satoh, A., Ono, K., Komatsu, Y.
Published in Annals of oncology (01.11.2018)

Get full text

Journal Article

Updated analysis and exploratory analysis of primary tumor location in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer

Updated analysis and exploratory analysis of primary tumor location in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer

by Nakamura, M, Takashima, A, Denda, T, Gamoh, M, Iwanaga, I, Komatsu, Y, Takahashi, M, Ohori, H, Sekikawa, T, Tsuda, M, Kobayashi, Y, Miyamoto, Y, Kotake, M, Ishioka, C, Shimada, K, Sato, A, Yuki, S, Morita, S, Takahashi, S, Yamaguchi, T
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

38P Modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab for right-sided or BRAF mutant metastatic colorectal cancer (mCRC): Subgroup analysis of the DEEPER trial (JACCRO CC-13)

38P Modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab for right-sided or BRAF mutant metastatic colorectal cancer (mCRC): Subgroup analysis of the DEEPER trial (JACCRO CC-13)

by Sunakawa, Y., Shiozawa, M., Kawai, T., Ota, H., Yasui, H., Kochi, M., Manaka, D., Ohori, H., Matsuura, M., Shinohara, Y., Takeuchi, M., Ichikawa, W., Fujii, M., Tsuji, A.
Published in Annals of oncology (01.06.2024)

Get full text

Journal Article

Haemagglutination and glycolipid‐binding activities of Lactobacillus reuteri

Haemagglutination and glycolipid‐binding activities of Lactobacillus reuteri

by Mukai, T., Kaneko, S., Ohori, H.
Published in Letters in applied microbiology (01.09.1998)

Get full text

Journal Article

90MO Panitumumab (PAN) vs bevacizumab (BEV) in metastatic colorectal cancer (mCRC) by microsatellite stable (MSS), RAS/BRAF, and HER2 amplification (HER2amp) status: Phase III PARADIGM biomarker study

90MO Panitumumab (PAN) vs bevacizumab (BEV) in metastatic colorectal cancer (mCRC) by microsatellite stable (MSS), RAS/BRAF, and HER2 amplification (HER2amp) status: Phase III PARADIGM biomarker study

by Kato, T., Muro, K., Watanabe, J., Shitara, K., Yamazaki, K., Ohori, H., Shiozawa, M., Yasui, H., Oki, E., Sato, T., Naitoh, T., Komatsu, Y., Soeda, J., Yamamoto, K., Yamashita, R., Akagi, K., Ochiai, A., Uetake, H., Tsuchihara, K., Yoshino, T.
Published in Annals of oncology (01.11.2023)

Get full text

Journal Article

555MO Modified (m)-FOLFOXIRI plus cetuximab treatment and predictive clinical factors for RAS/BRAF wild-type and left-sided metastatic colorectal cancer (mCRC): The DEEPER trial (JACCRO CC-13)

555MO Modified (m)-FOLFOXIRI plus cetuximab treatment and predictive clinical factors for RAS/BRAF wild-type and left-sided metastatic colorectal cancer (mCRC): The DEEPER trial (JACCRO CC-13)

by Sunakawa, Y., Shiozawa, M., Watanabe, T., Ota, H., Yasui, H., Kochi, M., Manaka, D., Ohori, H., Yamaguchi, T., Matsuura, M., Shinohara, Y., Miyake, T., Sagawa, T., Tanaka, C., Okamura, S., Takeuchi, M., Ichikawa, W., Fujii, M., Tsuji, A.
Published in Annals of oncology (01.10.2023)

Get full text

Journal Article

388P Early tumor shrinkage (ETS) and depth of response (DpR) analyses in metastatic colorectal cancer (mCRC) treated with first-line mFOLFOX6 plus panitumumab (PAN) or bevacizumab (BEV): Results from the phase III PARADIGM trial

388P Early tumor shrinkage (ETS) and depth of response (DpR) analyses in metastatic colorectal cancer (mCRC) treated with first-line mFOLFOX6 plus panitumumab (PAN) or bevacizumab (BEV): Results from the phase III PARADIGM trial

by Muro, K., Watanabe, J., Shitara, K., Yamazaki, K., Ohori, H., Shiozawa, M., Yasui, H., Oki, E., Sato, T., Naitoh, T., Komatsu, Y., Kato, T., Hihara, M., Soeda, J., Yamamoto, K., Akagi, K., Ochiai, A., Uetake, H., Tsuchihara, K., Yoshino, T.
Published in Annals of oncology (01.09.2022)

Get full text

Journal Article

LBA O-10 First-line panitumumab versus bevacizumab in combination with mFOLFOX6 for RAS wild-type metastatic colorectal cancer: PARADIGM trial results

LBA O-10 First-line panitumumab versus bevacizumab in combination with mFOLFOX6 for RAS wild-type metastatic colorectal cancer: PARADIGM trial results

by Muro, K., Watanabe, J., Shitara, K., Yamazaki, K., Ohori, H., Shiozawa, M., Yasui, H., Oki, E., Sato, T., Naitoh, T., Komatsu, Y., Kato, T., Hihara, M., Soeda, J., Yamamoto, K., Akagi, K., Ochiai, A., Uetake, H., Yoshino, T.
Published in Annals of oncology (01.06.2022)

Get full text

Journal Article

SO-25 Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment for RAS and BRAF wild-type metastatic colorectal cancer: Updated survival analysis of the DEEPER trial by JACCRO

SO-25 Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment for RAS and BRAF wild-type metastatic colorectal cancer: Updated survival analysis of the DEEPER trial by JACCRO

by Sunakawa, Y., Shiozawa, M., Watanabe, T., Ota, H., Yasui, H., Kochi, M., Manaka, D., Ohori, H., Yamaguchi, T., Kyogoku, T., Sagawa, T., Kubota, Y., Masuishi, T., Kotaka, M., Sekikawa, T., Shimada, K., Nakamura, M., Takeuchi, M., Ichikawa, W., Fujii, M., Tsuji, A.
Published in Annals of oncology (01.06.2023)

Get full text

Journal Article

Collagen binding of Bifidobacterium adolescentis

Collagen binding of Bifidobacterium adolescentis

by MUKAI, T, TOBA, T, OHORI, H
Published in Current microbiology (01.05.1997)

Get full text

Journal Article

Serum HER2 Extracellular Domain Levels and Tissue HER2 Overexpression in Advanced Gastric Cancer Patients

Serum HER2 Extracellular Domain Levels and Tissue HER2 Overexpression in Advanced Gastric Cancer Patients

by Takahashi, Y., Ohori, H., Takahashi, M., Gamoh, M.
Published in Annals of oncology (01.11.2013)

Get full text

Journal Article

Serum HER2ECD Levels in Patients with Advanced Gastric Cancer Treated with Trastuzumab as First-Line Therapy

Serum HER2ECD Levels in Patients with Advanced Gastric Cancer Treated with Trastuzumab as First-Line Therapy

by Takahashi, M., Takahashi, Y., Ohori, H., Gamoh, M.
Published in Annals of oncology (01.11.2013)

Get full text

Journal Article

PD-013RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC)

PD-013RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC)

by Sunakawa, Y, Nakamura, M, Nakamura, M, Ishizaki, M, Kataoka, M, Satake, H, Kitazono, M, Yanagisawa, H, Kawamoto, Y, Kuramochi, H, Ohori, H, Takahashi, K, Maeda, F, Komeno, C, Takeuchi, M, Fujii, M, Yoshino, T, Ichikawa, W, Tsuji, A
Published in Annals of oncology (01.07.2019)

Get full text

Journal Article

Comparison of Docetaxel and Paclitaxel for Advanced Esophageal Cancer After Progression on Platinum-Based Chemotherapy

Comparison of Docetaxel and Paclitaxel for Advanced Esophageal Cancer After Progression on Platinum-Based Chemotherapy

by Ohori, H., Takahashi, Y., Takahashi, M., Gamoh, M.
Published in Annals of oncology (01.11.2013)

Get full text

Journal Article

452TiPA feasibility study of edoxaban for the cancer-associated asymptomatic venous thromboembolism in Japanese gastrointestinal cancer patients receiving chemotherapy (ExCAVE study)

452TiPA feasibility study of edoxaban for the cancer-associated asymptomatic venous thromboembolism in Japanese gastrointestinal cancer patients receiving chemotherapy (ExCAVE study)

by Nakamura, M, Yagisawa, M, Saiki, T, Ishiguro, A, Sawada, K, Yuki, S, Sasaki, T, Ando, T, Ohori, H, Kotaka, M, Muto, O, Shindo, Y, Nakashima, K, Hosokawa, A, Doi, A, Izawa, N, Sunakawa, Y, Satoh, A, Ono, K, Komatsu, Y
Published in Annals of oncology (01.11.2018)

Get full text

Journal Article

475PUpdated analysis and exploratory analysis of primary tumor location in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer

475PUpdated analysis and exploratory analysis of primary tumor location in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer

by Nakamura, M, Takashima, A, Denda, T, Gamoh, M, Iwanaga, I, Komatsu, Y, Takahashi, M, Ohori, H, Sekikawa, T, Tsuda, M, Kobayashi, Y, Miyamoto, Y, Kotake, M, Ishioka, C, Shimada, K, Sato, A, Yuki, S, Morita, S, Takahashi, S, Yamaguchi, T
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

Depletion of dietary sulphamonomethoxine and sulphadimethoxine from various tissues of laying hens

Depletion of dietary sulphamonomethoxine and sulphadimethoxine from various tissues of laying hens

by Furusawa, N, Mukai, T, Ohori, H
Published in British poultry science (01.05.1996)

Get more information

Journal Article

DNA-binding activity of hepatitis B e antigen polypeptide lacking the protaminelike sequence of nucleocapsid protein of human hepatitis B virus

DNA-binding activity of hepatitis B e antigen polypeptide lacking the protaminelike sequence of nucleocapsid protein of human hepatitis B virus

by MATSUDA, K, SATOH, S, OHORI, H
Published in Journal of Virology (01.09.1988)

Get full text

Journal Article